OM Pharma Pediatric Wheezing Screening |
This is a 9-month Phase 2, randomized, double-blind, placebo-controlled,
multicenter study to assess the efficacy and safety of daily treatment with OM-85 compared to placebo, when given on top of standard of care treatment, in reducing wheezing events (WEs) during the 6-month Treatment period in children aged 6 months to 5 years with previous recurrent WEs.
multicenter study to assess the efficacy and safety of daily treatment with OM-85 compared to placebo, when given on top of standard of care treatment, in reducing wheezing events (WEs) during the 6-month Treatment period in children aged 6 months to 5 years with previous recurrent WEs.